Active	Status	Sponsor type	Region	Phase	Filter
17 Active 6 Inactive 23 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lee, Christopher
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema	Recruiting	2	150	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin Co., Ltd.	Diabetic Macular Edema (DME)	11/25	12/25
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration	Recruiting	2	180	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin Co., Ltd.	Neovascular Age-Related Macular Degeneration (nAMD)	11/25	12/25
Yu, Seung Taek
Aladdin, NCT04618640: To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years	Recruiting	3	249	RoW	DTaP-IPV combination vaccine	Boryung Biopharma Co., Ltd.	Diphtheria, Tetanus, Pertussis, Poliomyelitis	12/20	07/21
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema	Recruiting	2	150	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin Co., Ltd.	Diabetic Macular Edema (DME)	11/25	12/25
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration	Recruiting	2	180	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin Co., Ltd.	Neovascular Age-Related Macular Degeneration (nAMD)	11/25	12/25
Yagi, Fumihiko
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema	Recruiting	2	150	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin Co., Ltd.	Diabetic Macular Edema (DME)	11/25	12/25
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration	Recruiting	2	180	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin Co., Ltd.	Neovascular Age-Related Macular Degeneration (nAMD)	11/25	12/25
Suzuma, Kiyoshi
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema	Recruiting	2	150	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin Co., Ltd.	Diabetic Macular Edema (DME)	11/25	12/25
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration	Recruiting	2	180	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin Co., Ltd.	Neovascular Age-Related Macular Degeneration (nAMD)	11/25	12/25
Miyamoto, Noriko
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema	Recruiting	2	150	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin Co., Ltd.	Diabetic Macular Edema (DME)	11/25	12/25
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration	Recruiting	2	180	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin Co., Ltd.	Neovascular Age-Related Macular Degeneration (nAMD)	11/25	12/25